首页> 外文期刊>Biomedicine & pharmacotherapy =: Biomedecine & pharmacotherapie >RNA sequencing reveals the long noncoding RNA and mRNA profiles and identifies long non-coding RNA TSPAN12 as a potential microvascular invasion-related biomarker in hepatocellular carcinoma
【24h】

RNA sequencing reveals the long noncoding RNA and mRNA profiles and identifies long non-coding RNA TSPAN12 as a potential microvascular invasion-related biomarker in hepatocellular carcinoma

机译:RNA测序揭示了长的非分量RNA和mRNA谱,并将长的非编码RNA TSPAN12鉴定为肝细胞癌中潜在的微血管侵袭相关生物标志物

获取原文
获取原文并翻译 | 示例
           

摘要

Emerging evidence demonstrates that abnormally expressed long noncoding RNAs (lncRNAs) are involved in the progression of various cancers. However, the expression profiles and functions of lncRNAs in hepatocellular carcinoma (HCC) with microvascular invasion (MVI) remain largely unknown. In this study, we revealed the differential expression profiles of lncRNA and messenger RNA in four pairs of HCC with MVI and adjacent nontumor liver tissues by using high-throughput RNA sequencing. Among these dysregulated lncRNAs, lnc-TSPAN12 was the most significantly upregulated lncRNA in HCC. The results of real time-PCR showed that lnc-TSPAN12 was highly expressed in HCC, including HCC with MVI, and its high expression was associated with unfavorable clinicopathological features and poor prognosis. Moreover, multivariate Cox regression analysis verified that lnc-TSPAN12 was an independent prognostic predictor for overall and recurrence-free survival. Receiver operating characteristic curve analysis indicated that lnc-TSPAN12 could serve as a potential diagnostic biomarker for HCC with MVI. In addition, a loss-of-function experiment demonstrated that lnc-TSPAN12 knockdown inhibited HCC cell migration and invasion in vitro. Our findings suggest that lnc-TSPAN12 may function as an oncogene in HCC progression and could serve as a novel diagnostic/prognostic biomarker and potential therapeutic target for HCC with MVI.
机译:新兴的证据表明,异常表达的长度非编码RNA(LNCRNA)参与各种癌症的进展。然而,具有微血管侵袭(MVI)的肝细胞癌(HCC)中LNCRNA的表达谱和功能仍然很大程度上是未知的。在这项研究中,通过使用高通量RNA测序,通过使用高通量RNA测序揭示了用MVI和相邻的Nontumor肝组织的四对HCC中LNCRNA和信使RNA的差异表达谱。在这些疑虑的LNCRNA中,LNC-Tspan12是HCC中最显着上调的LNCRNA。实时PCR的结果表明,LNC-TSPAN12在HCC中高度表达,包括具有MVI的HCC,其高表达与不利的临床病理特征有关,预后不良。此外,多元COX回归分析证实,LNC-Tspan12是整体和复发的存活的独立预测预测因子。接收器操作特征曲线分析表明,LNC-Tspan12可以用作具有MVI的HCC的潜在诊断生物标志物。此外,功能丧失实验表明,LNC-Tspan12敲低抑制了HCC细胞迁移和体外侵袭。我们的研究结果表明,LNC-Tspan12可以用作HCC进展中的癌基因,并且可以作为具有MVI的新型诊断/预后生物标志物和HCC的潜在治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号